Mustafa Erdem Arslan

Dr. Mustafa Erdem Arslan

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FOFarideh Ordikhani
Farideh Ordikhani
MAMustafa Erdem Arslan
Mustafa Erdem Arslan
RMRaymundo Marcelo
Raymundo Marcelo
ISIlyas Sahin
Ilyas Sahin
PGPerry Grigsby
Perry Grigsby
KAKareem Azab
Kareem Azab
Cervical cancer is a highly prevalent cancer that affects women around the world. With the availability of new technologies, researchers have increased their efforts to develop new drug delivery systems in cervical cancer chemotherapy. In this review, we summarized some of the recent research in systematic and localized drug delivery systems and compared the advantages and disadvantages of these methods.

15 July 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
RVRobert Pantaleon Vasquez
Robert Pantaleon Vasquez
MAMustafa Erdem Arslan
Mustafa Erdem Arslan
HLHwajeong Lee
Hwajeong Lee
TKTonya S. King
Tonya S. King
DDDeepti Dhall
Deepti Dhall
DKDipti M. Karamchandani
Dipti M. Karamchandani

1 October 2020 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
MAMustafa Erdem Arslan
Mustafa Erdem Arslan
HLHua Li
Hua Li
TJTimothy A. Jennings
Timothy A. Jennings
ELEdward C. Lee
Edward C. Lee
ANAnkesh Nigam
Ankesh Nigam
HLHwajeong Lee
Hwajeong Lee

1 January 2022 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
MRMark Riley
Mark Riley
PMPaul Der Mesropian
Paul Der Mesropian
AMAna Maheshwari
Ana Maheshwari
MAMustafa Erdem Arslan
Mustafa Erdem Arslan
PVParth Visrodia
Parth Visrodia
KHKrishnakumar Hongalgi
Krishnakumar Hongalgi
Systemic sclerosis with negative serology, particularly that complicated by scleroderma renal crisis (SRC), is rarely encountered. We describe a patient with seronegative systemic sclerosis who developed acute kidney injury, proteinuria, and hypertensive emergency following motor vehicle-related trauma and in the setting of nonsteroidal anti-inflammatory drug use. Findings on physical examination, imaging, and skin biopsy led to a clinical diagnosis of scleroderma, despite the lack of supportive laboratory data. IgG lambda paraproteinemia was detected on workup. Bone marrow biopsy showed plasmacytosis and trace lambda-restricted plasma cells consistent with monoclonal gammopathy of undetermined significance. Chemotherapy was initially started given concern for myeloma with cast nephropathy but was later stopped after a kidney biopsy revealed thrombotic microangiopathy (TMA). The SRC associated with TMA was ultimately diagnosed, though atypical hemolytic uremic syndrome (aHUS) induced perhaps by monoclonal gammopathy or hypertension was also possible. Captopril and eculizumab were initiated for SRC and aHUS, respectively. Despite therapy, renal function did not recover, and the patient required hemodialysis indefinitely. This case highlights clinical features common to both SRC and aHUS as well as points out a few ways to differentiate between them.

13 June 2020 in Cureus
Verified
Journal Article
Open access
PDF file
HLHua Li
Hua Li
PEPeter Ells
Peter Ells
MAMustafa Erdem Arslan
Mustafa Erdem Arslan
KRKarl A Robstad
Karl A Robstad
HLHwajeong Lee
Hwajeong Lee
Langerhans cell histiocytosis (LCH) is a rare systemic disorder characterized by an infiltration of CD1a+/langerin+ histiocytes, commonly involving bone, skin, and lymph nodes in children. Hepatic involvement is rarely observed in multisystem LCH. We describe an exceptional case of hepatic LCH in an adult preceding the diagnosis of multisystem LCH, mimicking anti-mitochondrial antibody (AMA)-negative primary biliary cholangitis (PBC). A 65-year-old man presented with intermittent pruritus, weakness, dyspnea, fever, and chills that have been progressive for four years. Physical examination was unremarkable. Laboratory work revealed cholestatic biochemistry profile. Liver biopsy showed portal non-necrotizing granuloma encasing a damaged duct (florid duct lesion), and multifocal lobular Kupffer cell clusters, suggestive of PBC. Tests for autoimmune diseases including AMA were negative. Endoscopic retrograde cholangiopancreatography (ERCP) was negative for biliary obstruction. One month after the liver biopsy, he developed flaky, red, and burning rash on the right scalp, forehead, and epigastric skin. A skin biopsy at an outside institution revealed LCH. Subsequent re-examination of the liver biopsy showed that the histiocytes within the florid duct lesion were positive for CD1a and S-100. Concurrently, a small focus of LCH was noted in his gastric biopsy performed for gastritis symptoms. Hepatic LCH may mimic AMA-negative PBC histologically and clinically and may present as a harbinger of multisystem LCH. While rendering the diagnosis would be challenging without prior history of LCH and with focal involvement, awareness of such presentation and communication with clinical colleagues may be helpful.

1 February 2023 in Academic Pathology
Verified
Journal Article
Open access
MKMichel Kmeid
Michel Kmeid
RBRupinder Brar
Rupinder Brar
LSLuz Sullivan
Luz Sullivan
MAMustafa Erdem Arslan
Mustafa Erdem Arslan
NSNeharika Shrestha
Neharika Shrestha
HLHwajeong Lee
Hwajeong Lee
Patients with rectal cancer undergo more repeat biopsies compared to those with nonrectal colon cancer prior to management. We investigated the factors driving the higher frequency of repeat biopsies in patients with rectal cancer. We compared clinicopathologic features of diagnostic and nondiagnostic (in regard to invasion) rectal (n = 64) and colonic (n = 57) biopsies from colorectal cancer patients and characterized corresponding resections. Despite similar diagnostic yield, repeat biopsy was more common in rectal carcinoma, especially in patients receiving neoadjuvant therapy (p < 0.05). The presence of desmoplasia (odds ratio 12.9, p < 0.05) was a strong predictor of making a diagnosis of invasion in both rectal and nonrectal colon cancer biopsies. Diagnostic biopsies had more desmoplasia, intramucosal carcinoma component and marked inflammation, and less low-grade dysplasia component (p < 0.05). Diagnostic yield of biopsy was higher for tumors with high-grade tumor budding, mucosal involvement by high-grade dysplasia/intramucosal carcinoma without low-grade dysplasia and diffuse surface desmoplasia irrespective of tumor location. Sample size, amount of benign tissue, appearance, and T stage did not affect diagnostic yield. Repeat biopsy of rectal cancer is primarily driven by management implications. Diagnostic yield in colorectal cancer biopsies is multifactorial and is not due to differing pathologists' diagnostic approach per tumor site. For rectal tumors, a multidisciplinary strategic approach is warranted to avoid repeat biopsy when unnecessary.